share_log

Wedbush Reiterates Neutral on Fate Therapeutics, Maintains $7 Price Target

Benzinga ·  May 6 08:23

Wedbush analyst David Nierengarten reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $7 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment